Imperial College London
Alternate

DrGoedeleMaertens

Faculty of Medicine, Department of Infectious Disease

Reader in Molecular Virology
 
 
 
//

Contact

 

+44 (0)20 7594 3655g.maertens Website

 
 
//

Location

 

314, Medical School BuildingNorfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Schneiderman:2022:10.3389/fmed.2022.889621,
author = {Schneiderman, B and Barski, M and Maertens, G},
doi = {10.3389/fmed.2022.889621},
journal = {Frontiers in Medicine},
pages = {1--7},
title = {Cabotegravir, the long-acting integrase strand transfer inhibitor, potently inhibits HTLV-1 transmission in vitro},
url = {http://dx.doi.org/10.3389/fmed.2022.889621},
volume = {9},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Human T cell Lymphotropic Virus Type 1 (HTLV-1) is a deltaretrovirus most prevalent in Southwestern Japan, sub-Saharan Africa, Australia, South America and the Carribean. Latest figures approximate 10 million people worldwide to be infected with HTLV-1. This is likely a significant underestimation due to lack of screening in endemic areas and absence of seroconversion symptoms. The two primary diseases associated with HTLV-1 infection are adult T cell leukaemia-lymphoma, a malignant and, sometimes, aggressive cancer; and HTLV-1 associated yelopathy/tropicalspastic paraparesis, a debilitating neurological degenerative disease. Unfortunately, despite the poor prognosis, there is currently no effective treatment for HTLV-1 infection. We previously showed that integrase strand transfer inhibitors (INSTIs) clinically used for HIV-1 prophylaxis and treatment are also effective against HTLV-1 transmission in vitro. In 2021 a new INSTI, cabotegravir, was approved by the FDA for HIV-1 treatment. We thus set out to evaluate its efficacy against HTLV-1 infection in vitro. Strand transfer assays performed using recombinant HTLV-1 integrase treated with increasing concentrations of cabotegravir, effectively inhibited strandtransfer activity, displaying an IC50 of 77.8 ± 22.4 nM. Furthermore, cabotegravir blocked HTLV-1 transmission in tissue culture; we determined an EC50 of 0.56 ±0.26 nM, similar to bictegravir. Alu-PCR confirmed the block in integration. Thus, there are 4 INSTIs and 1 reverse transcriptase inhibitor approved by the FDA for HIV-1 treatment, that potently block HTLV-1 infection in vitro. This should strongly encourage the establishment of a new standard of HTLV-1 treatment – particularly for pre-exposure prophylaxis and prevention of mother-to-child transmission.
AU  - Schneiderman,B
AU  - Barski,M
AU  - Maertens,G
DO  - 10.3389/fmed.2022.889621
EP  - 7
PY  - 2022///
SN  - 2296-858X
SP  - 1
TI  - Cabotegravir, the long-acting integrase strand transfer inhibitor, potently inhibits HTLV-1 transmission in vitro
T2  - Frontiers in Medicine
UR  - http://dx.doi.org/10.3389/fmed.2022.889621
UR  - https://www.frontiersin.org/articles/10.3389/fmed.2022.889621/full
UR  - http://hdl.handle.net/10044/1/96702
VL  - 9
ER  -
Download